-
Study aim
-
Compression of intranasal ketamine, intranasal fentanyl adjunct to intravenous ketorolac on renal colic pain relief
-
Design
-
Randomized control trial, randomization by random schedule, double blinded, 3 parallel groups (40 patients in each group)
-
Settings and conduct
-
120 patients admitted to the emergency department of Shahid Sadoughi and Shahid Rahnemoon hospitals in Yazd based on inclusion and exclusion criteria will be randomly allocated into three groups: Group A: 1 milligram per kilogram intranasal ketamine and 30 milligrams intravenous ketorolac, group B: 1 microgram per kilogram intranasal fentanyl and 30 milligrams intravenous ketorolac and for group C nasal placebo spray and 30 milligrams intravenous ketorolac will be prescribed and the severity of pain (by Visual Analogue Scale score) and complications of drugs will be determined in 0, 5, 10, 15, 30 and 60 minutes. The drugs will be prescribed by a triage nurse and none of patients nor physician won't know which drug was to be prescribed.
-
Participants/Inclusion and exclusion criteria
-
All 15 to 64 years old patients suspected for renal colic and urolithiasis based on urine analysis and imaging (ultrasonography or CT scan) , history and physical examination;
Pregnancy, fever, hemodynamic instability, allergy or addiction to prescribed medication, nasal congestion, history of renal, cardiac or hepatic failure, brain tumor, glaucoma, peptic ulcer and psychosis, consumption of analgesic drugs in 4 last hours, VAS score below 5
-
Intervention groups
-
Group A: 1 milligram per kilogram intranasal ketamine (maximum 50 milligrams) and 30 milligrams intravenous ketorolac
Group B: 1 microgram per kilogram intranasal fentanyl (maximum 50 micrograms) and 30 milligrams intravenous ketorolac
Group C: nasal placebo spray and 30 milligrams intravenous ketorolac
-
Main outcome variables
-
Severity of pain measured by Visual Analogue Scale